Repetitive exposure to TGF-β suppresses TGF-β type I receptor expression by differentiated osteoblasts

被引:14
|
作者
Kim, Kenneth K.
Ji, Changhua
Chang, Weizhong
Wells, Rebecca G.
Gundberg, Caren M.
McCarthy, Thomas L.
Centrella, Michael
机构
[1] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06520 USA
[3] Univ Penn, Sch Med, Dept Med Pathol & Lab Med, Philadelphia, PA USA
关键词
bone; runx; gene promoter; transcription;
D O I
10.1016/j.gene.2006.05.005
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Transforming growth factor-beta (TGF-beta) has potent, cell phenotype restricted effects. In bone, it controls multiple activities by osteoblasts through three predominant receptors. Of these, the relative amounts of TGF-beta receptor I (T beta RI) vary directly with TGF-beta sensitivity. The rat T beta RI gene promoter includes cis-acting elements for transcription factor Runx2. Here we show conservation and selective partitioning of T beta RI and retention of TGF-beta activity with osteoblast differentiation, Runx2 binding to the T beta RI gene promoter on osteoblast chromatin, and decreased promoter activity by Runx2 binding site mutation. Furthermore, in contrast to the stimulatory effects induced by single or limited exposure to TGF-beta, we found that osteoblasts became resistant to TGF-beta after high dose and repetitive treatment. T beta RI protein, mRNA, and gene-promoter activity all decreased after. three daily TGF-beta treatments, in parallel with a reduction in Runx2 protein and Runx dependent gene expression. In this way, sustained TGF-beta exposure can limit its own effectiveness by suppressing the expression of its primary signaling receptor. This tightly controlled system may constitute a feedback loop to protect against TGF-beta excess, and impose important limitations that are required for the progression of events during skeletal growth, remodeling and repair. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:175 / 184
页数:10
相关论文
共 50 条
  • [31] Fibroblasts from chronic wounds show altered TGF-β-signaling and decreased TGF-β type II receptor expression
    Kim, BC
    Kim, HT
    Park, SH
    Cha, JS
    Yufit, T
    Kim, SJ
    Falanga, V
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 195 (03) : 331 - 336
  • [32] TGF-β1 Suppresses p53 Expression and Induces Resistance to Apoptosis in Colorectal Cancer Cells Lacking Functional Type II TGF-β Receptor
    Tsujii, Yoshiki
    Hayashi, Yoshito
    Tsujii, Masahiko
    Yoshii, Shunsuke
    Nagai, Kengo
    Fujinaga, Tetsuji
    Maekawa, Akira
    Inoue, Takuya
    Watabe, Kenji
    Iijima, Hideki
    Takehara, Tetsuo
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S954 - S954
  • [33] Evaluation of the prognostic value of TGF-β superfamily type I receptor and TGF-β type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays
    Zhang, Wenling
    Zeng, Zhaoyang
    Fan, Songqing
    Wang, Jieru
    Yang, Jianbo
    Zhou, Yanhong
    Li, Xiayu
    Huang, Donghai
    Liang, Fang
    Wu, Minghua
    Tang, Ke
    Cao, Li
    Li, Xiaoling
    Xiong, Wei
    Li, Guiyuan
    [J]. JOURNAL OF MOLECULAR HISTOLOGY, 2012, 43 (03) : 297 - 306
  • [34] The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-β signaling by inactivating the TGF-β type II receptor
    Jin, W
    Kim, BC
    Tognon, C
    Lee, HJ
    Patel, S
    Lannon, CL
    Maris, JM
    Triche, TJ
    Sorensen, PHB
    Kim, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (45) : 16239 - 16244
  • [35] Evaluation of the prognostic value of TGF-β superfamily type I receptor and TGF-β type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays
    Wenling Zhang
    Zhaoyang Zeng
    Songqing Fan
    Jieru Wang
    Jianbo Yang
    Yanhong Zhou
    Xiayu Li
    Donghai Huang
    Fang Liang
    Minghua Wu
    Ke Tang
    Li Cao
    Xiaoling Li
    Wei Xiong
    Guiyuan Li
    [J]. Journal of Molecular Histology, 2012, 43 : 297 - 306
  • [36] TGF-β sensitivity is determined by N-linked glycosylation of the type II TGF-β receptor
    Kim, Young-Woong
    Park, Jinah
    Lee, Hyun-Ju
    Lee, So-Young
    Kim, Seong-Jin
    [J]. BIOCHEMICAL JOURNAL, 2012, 445 : 403 - 411
  • [37] TGF-β1, TGF-β receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy
    Bochaton-Piallat, ML
    Kapetanios, AD
    Donati, G
    Redard, M
    Gabbiani, G
    Pournaras, CJ
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (08) : 2336 - 2342
  • [38] Sorafenib supresses TGF-β responsiveness by promoting TGF-β type II receptor degradation.
    Wang, Shi-Weigh
    [J]. FASEB JOURNAL, 2018, 32 (01):
  • [39] The type I TGF-β receptor is covalently modified and regulated by sumoylation
    Kang, Jong Seok
    Saunier, Elise F.
    Akhurst, Rosemary J.
    Derynck, Rik
    [J]. NATURE CELL BIOLOGY, 2008, 10 (06) : 654 - 664
  • [40] The type I TGF-β receptor is covalently modified and regulated by sumoylation
    Jong Seok Kang
    Elise F. Saunier
    Rosemary J. Akhurst
    Rik Derynck
    [J]. Nature Cell Biology, 2008, 10 : 654 - 664